Pregabalin Effect on Acute and Chronic Pain after Cardiac Surgery
Table 1
Demographic and clinical patient characteristics. Data reported as mean ± SD, median (range), or number of patients, as appropriate. Values were compared between groups using ANOVA, Kruskal-Wallis, or Chi-square tests as appropriate. values for significance were adjusted to 0.05/20 = 0.0025 using Bonferroni correction for multiple comparisons.
Variable
Group 1 (control)
Group 2 (pregabalin 75 mg)
Group 3 (pregabalin 150 mg)
Age
66.1 ± 10.2
67.4 ± 7.8
67.8 ± 6.8
0.705
Sex (M/F)
21/10
19/12
17/14
0.58
Weight
82.2 ± 14.5
80.3 ± 12.0
79.6 ± 8.9
0.665
Height
1.70 ± 0.07
1.68 ± 0.07
1.67 ± 0.07
0.342
BMI
28.6 ± 4.8
28.4 ± 3.9
28.6 ± 3.2
0.973
Operation time
243.2 ± 29.6
244.7 ± 24.2
221.9 ± 27.4
0.002
ASA status
3 (3, 4)
3 (3, 4)
3 (3, 4)
0.109
Hypertension
18
23
28
0.015
Diabetes
15
13
9
0.285
Hyperlipidemia
21
19
22
0.713
Arrhythmias
3
7
0
0.016
Thyroid disease
0
3
1
0.161
Statins
24
23
24
0.942
B-blockers
25
16
20
0.030
Ca channel antagonists
8
8
8
1.000
Diuretics
9
10
11
0.863
ACE inhibitors
10
10
7
0.625
ARBs
10
8
9
0.855
Nitrates
6
4
3
0.535
Antiplatelet agents
12
19
16
0.204
ACE = angiotensin-converting enzyme, ANOVA = Analysis of Variance, ARBs = Angiotensin Receptor Blockers, ASA = American Society of Anesthesiologists, AVR = Aortic Valve Replacement, CABG = Coronary Artery Bypass Graft, MVR = Mitral Valve Replacement.
